Abstract:In the past decade, fludarabine has had a major impact in increasing the effectiveness of treatment of patients with indolent B-cell malignancies. This has come about in a variety of clinical circumstances, including use of fludarabine alone as well as in combinations with DNA-damaging agents or membrane-targeted antibodies. Other strategies have used fludarabine to reduce immunological function, thus facilitating non-myeloablative stem cell transplants.Fludarabine is a prodrug that is converted to the free nucleoside 9-β-D-arabinosyl-2-fluoroadenine (F-ara-A) which enters cells and accumulates mainly as the 5′-triphosphate, F-ara-ATP. The rate-limiting step in the formation of triphosphate is conversion of F-ara-A to its monophosphate, which is catalyzed by deoxycytidine kinase. Although F-ara-A is not a good substrate for this enzyme, the high specific activity of this protein results in efficient phosphorylation of F-ara-A in certain tissues. F-ara-ATP has multiple mechanisms of action, which are mostly directed toward DNA. These include inhibition of ribonucleotide reductase, incorporation into DNA resulting in repression of further DNA polymerisation, and inhibition of DNA ligase and DNA primase. Collectively these actions affect DNA synthesis, which is the major mechanism of F-ara-A-induced cytotoxicity Secondarily, incorporation into RNA and inhibition of transcription has been shown in cell lines.With the standard dose of fludarabine (25 to 30 mg/m2/day given over 30 minutes for 5 days), plasma concentrations of about 3 μmol/L F-ara-A are achieved at the end of each infusion. Serial sampling of leukaemia cells from patients receiving these standard doses of fludarabine has demonstrated that the peak concentrations of F-ara-ATP are achieved 4 hours after start of fludarabine infusion. Although there is heterogeneity among individuals with respect to rate of F-ara-ATP accumulation, the peak concentrations are generally proportional to the dose of the drug. Knowledge of the plasma pharmacokinetics of its principal nucleoside metabolite F-ara-A, and the cellular pharmacology of the proximal active metabolite, F-ara-ATP, has provided some understanding of the activity of fludarabine when used as a single agent. Preclinical studies directed toward learning the mechanisms of action of this agent have formed the basis for several mechanism-based strategies for its combination and scheduling with other agents.As a single agent fludarabine has been effective for the indolent leukaemias. Biochemical modulation strategies resulted in enhanced accumulation of cytarabine triphosphate and led to the use of fludarabine for the treatment of acute leukaemias. Combination of fludarabine with DNA damaging agents to inhibit DNA repair processes has been highly effective for indolent leukaemias and lymphomas. The current review brings together knowledge of the mechanisms of fludarabine, the state of understanding of the plasma pharmacokinetics, and cellular pharmacodynamics of fludarabine nucleotides. This may be useful in the design of future therapeutic approaches.

Sequential Arabinosylcytosin with or Without Fludarabine in Paracmastic Patients with Acute Myeloid Leukemia.

Primary Clinical Study of FA Regimen As Consolidation Therapy for Patients with Acute Myeloid Leukemia

Aclarubicin and Low-Dose Cytosine Arabinoside in Combination with Granulocyte Colony-Stimulating Factor in Treating Acute Myeloid Leukemia Patients with Relapsed or Refractory Disease and Myelodysplastic Syndrome: a Multicenter Study of 112 Chinese Patients.

Retrospective Comparison of Fludarabine in Combination with Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia.

Primary Clinical Research of FA Regimen as Consolidation Therapy for Patients with Acute Myeloid Leukemia

Fludarabine and Ara-C Combination for Treatment of Adult Acute Myelogenous Leukemia: Pharmacokinetic and Pharmacodynamic Effects

[Clinical Study on Fludarabine Combined with Cytarabine Regimen in the Treatment of Patients with Refractory and Relapsed Acute Myeloid Leukemia].

Influence of Fludarabine on Pharmacokinetics and Pharmacodynamics of Cytarabine: Implications for a Continuous Infusion Schedule.

Does High-Dose Cytarabine Cause More Fungal Infection in Patients with Acute Myeloid Leukemia Undergoing Consolidation Therapy

Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.

Therapeutic Efficacy of Patients with Acute Non-Lymphocytic Leukemia in Remission Treated with Intermediate-Dose Arabinoside and Fludarabine

Effect of fludarabine combined with cytarabine on the viability and metabolic enzymes of HL-60 cells

Preconditioning with Fludarabine, Busulfan and Cytarabine Versus Standard BuCy2 for Patients with Acute Myeloid Leukemia: a Prospective, Randomized Phase II Study

Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

Cellular and Clinical Pharmacology of Fludarabine

Efficacy and Safety of Fludarabine Combined with Cytarabine in the Treatment of Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL).

Efficacy and Safety Evaluation of Fludarabine-Based Chemotherapy Regimen for Patients with Non-Hodgkin Lymphoma A Meta-Analysis

A Preclinical Evaluation of Cytarabine Prodrug Nanofibers Assembled from Cytarabine-Lauric Acid Conjugate Toward Solid Tumors

Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis

Comparison Of Clinical Efficacy Of Cytarabine With Different Regimens In Postremission Consolidation Therapy For Adult T(8;21) Aml Patients: A Multicenter Retrospective Study In China

Fludarabine combined with colony-stimulating factor and cytarabine regimen for treatment of refractory or relapsed acute myeloid leukemia